Integrated DNA Technologies, Inc.

176 articles about Integrated DNA Technologies, Inc.

• Integrated DNA Technologies Unveils New Custom Vector Onboarding Tool to Optimize Gene Synthesis

  3/27/2024

  Global genomics solutions provider Integrated DNA Technologies is expanding its gene synthesis offerings with a new custom vector onboarding tool.

• Integrated DNA Technologies and Element Biosciences Accelerate Next Generation Sequencing Workflows for Element’s AVITI™ System

  2/5/2024

  Life sciences companies Integrated DNA Technologies (IDT) and Element Biosciences, Inc. have bolstered their partnership with products to enable more efficient and streamlined next generation sequencing (NGS) workflows for users of the AVITI System, an innovative sequencing and multi-omics platform based on Element’s novel avidity base chemistry.

• Integrated DNA Technologies Reveals Launch of xGen™ Products for Ultima Genomics®

  9/27/2023

  With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announces the availability of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform.

• Integrated DNA Technologies and Aldevron® Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers

  9/18/2023

  Integrated DNA Technologies and Aldevron® Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers.

• Integrated DNA Technologies Launches New Archer™ FUSIONPlex™ Core Solid Tumor Panel for Cancer Research

  4/17/2023

  Integrated DNA Technologies (IDT), a global genomics solutions provider, is supporting research labs worldwide with a new solution to optimize operational efficiency and the identification of solid cancer tumors.

• Integrated DNA Technologies Expands Access, Expedites Turnaround Time, for Minimal Residual Disease (MRD) Solutions for Cancer Research

  2/1/2023

  Integrated DNA Technologies Expands Access, Expedites Turnaround Time, for Minimal Residual Disease (MRD) Solutions for Cancer Research.

• Invitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc.

  12/20/2022

  Invitae today announced that it has completed a transaction with Integrated DNA Technologies, Inc. (IDT), which includes the sale of Next Generation Sequencing (NGS) research assays under the trademarked name Archer®, also known as the Research Use Only (RUO) kitted solutions.

• IDT Unveils New Solution to Accelerate Homology-Directed Repair Genome Editing Research

  2/9/2022

  Global genomics solutions provider Integrated DNA Technologies is empowering researchers to drive scientific discoveries in gene editing with the release of Alt-R HDR Donor Blocks, an improved solution for increasing homology-directed repair rates in large fragment knock-in experiments.

• Sherlock Biosciences and Integrated DNA Technologies (IDT) Announce Strategic Partnership for Manufacturing CRISPR SARS-CoV-2 Diagnostic and Research Products

  6/8/2020

  Sherlock Biosciences and Integrated DNA Technologies (IDT) today announced the companies have entered into a strategic collaboration to enable large-scale manufacturing of the Sherlock™ CR

• 

  Biopharma Update on the Novel Coronavirus: June 8

  6/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.

• IDT Announces Expansion of Coronavirus Products, Begins Accepting Pre-Orders for New COVID-19 Primer-Probe Panel in Ratios Set Forth in WHO-Charité/Berlin Test

  4/15/2020

  IDT’s new panel includes the Iowa Black-ZEN quencher probe technology recently approved for use in existing CDC EUA testing protocol

• IDT launches Alt-R™ HDR Design Tool and Templates

  3/5/2020

  New tool significantly increases HDR rates by providing optimized donor template design and simplified Cas9 guide RNA selection

• 

  China Coronavirus Update: Continued Spread, Run on Antivirals and Facemasks, Baby Diagnosed

  2/6/2020

  The most recent figure for the China coronavirus outbreak is 28,018 confirmed cases with 563 deaths in China. Chinese health authorities indicate 19 foreigners have been infected by the virus. There are reports that a Chinese newborn is the youngest person to become infected. The infant was diagn...

• CORRECTING and REPLACING IDT Offers Preferred Pricing and Early Access to Complete Portfolio of Coronavirus Research Tools

  1/30/2020

  Complete qPCR panel of the CDC-published sequences for coronavirus detection in addition to preferred pricing on gBlocks fragments and synthetic genes ordered for vaccine development

• IDT Launches Custom Enrichment Panels for Faster, Lower Cost NGS at ASHG 2019

  10/17/2019

  NGS Discovery Pools enable larger custom panels and low sample numbers to speed up discovery

• IDT Launches oPools™ Oligo Pools – the Longest, Highest Fidelity, and Ready-to-Use Custom Oligo Pools on the Market

  8/28/2019

  Long, high-yield oligos with industry-beating low error rate enable researchers to skip amplification steps and start projects immediately

• IDT and iGEM partnership helps young researchers break free and innovate in synthetic biology

  4/16/2019

  iGEM teams benefit from accessible synthesis with free IDT products and support

• Aldevron Releases GMP-Grade SpyFi™ Cas9 Nuclease

  3/12/2019

  Product is the result of a partnership with Integrated DNA Technologies, and provides clinical-stage clients with a critical raw material

• Correcting sickle cell–causing mutation with efficient CRISPR-Cas9 genome editing

  8/6/2018

  Genome editing using the CRISPR-Cas9 system has tremendous promise for therapeutic correction of genetic errors in human cells. Research published in Nature Medicine describes collaborative effort to reduce off-target CRISPR-Cas9 genome editing – removing barriers for human therapeutic applications

• Life Sciences PCR Market Strength Seen in Recent Acquisitions

  3/13/2018

  Companies that produce PCR products would be of interest to larger concerns given the need for better life sciences research and pharmaceutical pipelines.